To study the clinical effect of Xinshuai No.1 Formula（心衰1号）combined with sacubitril valsartan in the treatment of chronic heart failure with hypotension.

A hundred patients with chronic heart failure and hypotension treated in the hospital from August 2022 to July 2023 were selected and divided into observation group and control group according to the random number table method，with 50 patients in each group. The patients in the control group were treated with sacubitril valsartan，and those in the observation group were treated with Xinshuai No.1 Formula combined with sacubitril valsartan for 4 weeks. The efficacy of cardiac function，blood pressure changes，serum inflammatory factors，quality of life and adverse reactions were observed and compared between the two groups.

The effective rate of cardiac function in the observation group was 68.00%（34/50），which was significantly higher than that in the control group（48.00%，24/50）（P<0.05）. After treatment，the systolic blood pressure and diastolic blood pressure of the two groups were significantly increased（P<0.05），and the pressures of the observation group were significantly higher than those of the control group（P<0.05）. There was no significant difference in serum high-sensitivity C-reactive protein（hs-CRP），interleukin-6（IL-6）or tumor necrosis factor-α（TNF-α）between the two groups before treatment（P>0.05）. After treatment，the serum inflammatory factors of the two groups were significantly reduced，and the levels of the observation group were significantly lower than those of the control group（P<0.05）. After treatment，the physical domain score and total score of the Chinese version of the Minnesota Heart Failure Quality of Life Scale（MLHFQ）in the two groups were significantly decreased，and the physical domain score and total score of the MLHFQ in the observation group were significantly higher than those in the control group（P<0.05）. The incidence of adverse reactions in the observation group and the control group was 8.00%（4/50）and 10.00%（5/50）and the difference was not statistically significant（P>0.05）.

The clinical effect of Xinshuai No.1 Formula combined with sacubitril valsartan in the treatment of chronic heart failure with hypotension is satisfactory. It can better improve the cardiac function and blood pressure level，reduce the body's inflammatory response and improve the quality of life of patients，and the treatment is safe and reliable.